Rapport Therapeutics director granted 15,200 stock options
Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock.
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock. The options carry an exercise price of $35.21 per share and expire on June 10, 2036.
According to the terms, the 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through that vesting date. Following this grant, he holds 15,200 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,200 shares
Grant/Award
1 txn
Insider
PAUL STEVEN M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,200 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Options granted: 15,200 options
Exercise price: $35.21 per share
Underlying shares: 15,200 shares
+3 more
6 metrics
Options granted
15,200 options
Stock Option (Right to Buy) grant to director
Exercise price
$35.21 per share
Option exercise price for underlying common stock
Underlying shares
15,200 shares
Common stock underlying granted options
Total options after grant
15,200 options
Total held directly following this transaction
Vesting date
Earlier of June 10, 2027 or next annual meeting
Subject to continued service requirement
Expiration date
June 10, 2036
Option term end date
Key Terms
Stock Option (Right to Buy), exercise price, underlying security, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 35.2100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: Common Stock"
vesting financial
"shares underlying this option shall vest upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Rapport Therapeutics (RAPP) report for Steven M. Paul?
Rapport Therapeutics reported that director Steven M. Paul received a grant of stock options for 15,200 shares. These options give him the right to buy common stock at a fixed price, as part of his equity-based compensation package from the company’s board.
How many stock options did the Rapport Therapeutics (RAPP) director receive?
Steven M. Paul received stock options covering 15,200 shares of Rapport Therapeutics common stock. This entire amount represents a new grant, and after the transaction he directly holds 15,200 stock options tied to the company’s common shares, according to the Form 4 disclosure.
What is the exercise price of the new RAPP stock options granted to the director?
The newly granted stock options to director Steven M. Paul have an exercise price of $35.21 per share. This means he can purchase Rapport Therapeutics common stock at that fixed price once the options vest, regardless of the market price at that time.
When do Steven M. Paul’s Rapport Therapeutics (RAPP) options vest?
The 15,200 stock options will vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next annual meeting of stockholders. Vesting is conditional on his continued service with the company through that vesting date under the grant terms.
What is the expiration date of the new Rapport Therapeutics (RAPP) stock options?
The stock options granted to Steven M. Paul expire on June 10, 2036. After that date, any unexercised options become worthless. The long duration gives him an extended window to decide whether to exercise and purchase common shares at the fixed price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
